All In Biotech

NDA 209363 · Evofem INC

Solosec

Secnidazole · Oral · Nitroimidazole Antimicrobial

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Sep 15, 2017

Approved uses

4

Original approval plus efficacy supplements

Registered trials

10

5 Phase 3, 1 recruiting

FAERS reports

282

66 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2026.

SOLOSEC ® is a nitroimidazole antimicrobial indicated for: Treatment of bacterial vaginosis in female patients 12 years of age and older. ( 1.1 ) Treatment of trichomoniasis in patients 12 years of age and older. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Bacterial Vaginosis SOLOSEC is indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older [see Use in Specific Populations (8.1) and Clinical Studies (14) ]. 1.2 Trichomoniasis SOLOSEC is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis in patients 12 years of age and older. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, treat partners of infected patients simultaneously in order to prevent reinfection [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . 1.3 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: SOLOSEC is a nitroimidazole antimicrobial drug [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 26, 2022 Supplement 16 · Efficacy LabelLetter
  • Jan 26, 2022 Supplement 14 · Efficacy LabelLetter
  • Jun 30, 2021 Supplement 12 · Efficacy LetterLabel
  • Sep 15, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • SOLOSEC · SECNIDAZOLE 2GM/PACKET · GRANULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Secnidazole" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting78
  • nausea51
  • drug ineffective31
  • diarrhoea23
  • wrong technique in product usage process22
  • product taste abnormal21
  • headache20
  • dysgeusia18
  • abdominal pain17
  • malaise13
  • no adverse event13
  • abdominal discomfort11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20081
20102
20111
20122
20133
20161
201854
2019108
202064
202116
202210
202311
20243
20254
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Solosec (Secnidazole)

2024 spending

$56K

Beneficiaries

157

190 claims

Per beneficiary

$358

$280.72 per unit

View as table
YearSpending
2020$121,421
2021$86,936
2022$82,812
2023$70,234
2024$56,144

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 45 on PubMed

Sponsor: Evofem INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.